-
CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy.
Expert Opin Biol Ther. 2007 Aug;7(8):1257-66
PMID: 17696823
-
Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression.
Cancer Res. 2007 Oct 15;67(20):10019-26
PMID: 17942936
-
Cancer immunoediting: from immunosurveillance to tumor escape.
Nat Immunol. 2002 Nov;3(11):991-8
PMID: 12407406
-
Regulation of immune responses by L-arginine metabolism.
Nat Rev Immunol. 2005 Aug;5(8):641-54
PMID: 16056256
-
Tumor escape mechanism governed by myeloid-derived suppressor cells.
Cancer Res. 2008 Apr 15;68(8):2561-3
PMID: 18413722
-
IL-12 enhances the antitumor actions of trastuzumab via NK cell IFN-γ production.
J Immunol. 2011 Mar 15;186(6):3401-9
PMID: 21321106
-
Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12.
J Clin Oncol. 2005 Dec 1;23(34):8835-44
PMID: 16314644
-
Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma.
Clin Cancer Res. 2007 Jan 15;13(2 Pt 2):721s-726s
PMID: 17255300
-
Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells.
J Immunol. 2009 May 1;182(9):5693-701
PMID: 19380816
-
Myeloid-derived suppressor cells: linking inflammation and cancer.
J Immunol. 2009 Apr 15;182(8):4499-506
PMID: 19342621
-
Impaired response to interferon-gamma in activated macrophages due to tyrosine nitration of STAT1 by endogenous nitric oxide.
Br J Pharmacol. 2001 Jan;132(2):419-26
PMID: 11159690
-
Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes.
Cancer Res. 2009 Feb 15;69(4):1553-60
PMID: 19201693
-
Modulators of arginine metabolism support cancer immunosurveillance.
BMC Immunol. 2009 Jan 09;10:1
PMID: 19134173
-
Impaired interferon signaling is a common immune defect in human cancer.
Proc Natl Acad Sci U S A. 2009 Jun 2;106(22):9010-5
PMID: 19451644
-
Peroxynitrite inhibits T lymphocyte activation and proliferation by promoting impairment of tyrosine phosphorylation and peroxynitrite-driven apoptotic death.
J Immunol. 1999 Mar 15;162(6):3356-66
PMID: 10092790
-
Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice.
Proc Natl Acad Sci U S A. 1998 Jun 23;95(13):7556-61
PMID: 9636188
-
A critical function for type I interferons in cancer immunoediting.
Nat Immunol. 2005 Jul;6(7):722-9
PMID: 15951814
-
Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism.
J Immunol. 2002 Jan 15;168(2):689-95
PMID: 11777962
-
Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives.
Immunol Rev. 2008 Apr;222:180-91
PMID: 18364002
-
Myeloid-derived suppressor cells as regulators of the immune system.
Nat Rev Immunol. 2009 Mar;9(3):162-74
PMID: 19197294
-
Interferons, immunity and cancer immunoediting.
Nat Rev Immunol. 2006 Nov;6(11):836-48
PMID: 17063185
-
IFN-alpha-induced signal transduction, gene expression, and antitumor activity of immune effector cells are negatively regulated by suppressor of cytokine signaling proteins.
J Immunol. 2007 Apr 15;178(8):4832-45
PMID: 17404264
-
A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer.
J Immunol. 2009 Feb 15;182(4):2492-501
PMID: 19201905
-
Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.
Clin Cancer Res. 2005 Sep 15;11(18):6713-21
PMID: 16166452
-
Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice.
Int Immunopharmacol. 2009 Jul;9(7-8):900-9
PMID: 19336265
-
Mechanism of T cell tolerance induced by myeloid-derived suppressor cells.
J Immunol. 2010 Mar 15;184(6):3106-16
PMID: 20142361
-
The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse.
J Clin Invest. 2003 Jul;112(2):170-80
PMID: 12865406
-
Mechanisms of experimental cancer cachexia. Interaction between mononuclear phagocytes and colon-26 carcinoma and its relevance to IL-6-mediated cancer cachexia.
J Immunol. 1992 Jun 1;148(11):3674-8
PMID: 1534101
-
Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy.
J Natl Cancer Inst. 2004 Sep 1;96(17):1331-42
PMID: 15339971
-
Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine.
Cancer Res. 2010 Jan 1;70(1):68-77
PMID: 20028852
-
Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease.
J Immunol. 2005 Jan 15;174(2):636-45
PMID: 15634881
-
Interferon-alpha in tumor immunity and immunotherapy.
Cytokine Growth Factor Rev. 2002 Apr;13(2):119-34
PMID: 11900988
-
Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response to IFN-alpha compared with immune effector cells.
Clin Cancer Res. 2007 Sep 1;13(17):5010-9
PMID: 17785551
-
Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells.
J Immunol. 1998 Nov 15;161(10):5313-20
PMID: 9820504
-
Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma.
PLoS Med. 2007 May;4(5):e176
PMID: 17488182
-
Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells.
J Clin Invest. 2006 Oct;116(10):2777-90
PMID: 17016559
-
Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor capable of activating or suppressing CD8(+) T cells.
Blood. 2000 Dec 1;96(12):3838-46
PMID: 11090068
-
A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model.
Cancer Res. 2007 Aug 1;67(15):7477-86
PMID: 17671218
-
Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial.
Clin Cancer Res. 2009 Mar 15;15(6):2123-9
PMID: 19276257
-
Tumor-induced CD11b+Gr-1+ myeloid cells suppress T cell sensitization in tumor-draining lymph nodes.
J Immunol. 2008 Sep 1;181(5):3291-300
PMID: 18714001